DAWN
Day One Biopharmaceuticals Inc

1,833
Mkt Cap
$1.06B
Volume
208,837.00
52W High
$15.05
52W Low
$5.64
PE Ratio
-6.96
DAWN Fundamentals
Price
$8.80
Prev Close
$10.36
Open
$10.36
50D MA
$7.55
Beta
1.09
Avg. Volume
1.52M
EPS (Annual)
-$1.02
P/B
2.35
Rev/Employee
$724,646.41
Loading...
Loading...
News
all
press releases
Mersana Therapeutics To Be Acquired By Day One Biopharmaceuticals For Up To $285 Mln
(RTTNews) - Mersana Therapeutics, Inc. (MRSN), a biopharmaceutical company, Thursday, announced that it has entered a definitive agreement to be acquired by Day One Biopharmaceuticals through a...
Nasdaq News: Markets·3h ago
News Placeholder
More News
News Placeholder
MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal
The upfront purchase price of $25 alone represents a premium of 182% from Mersana’s closing price on Wednesday.
Stocktwits·3h ago
News Placeholder
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says
JPMorgan Chase & Co. lifted their target price on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an "overweight" rating in a research report on Friday...
MarketBeat·5d ago
News Placeholder
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading 8.5% Higher - Here's Why
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 8.5% - Still a Buy...
MarketBeat·5d ago
News Placeholder
Equities Analysts Issue Forecasts for DAWN FY2025 Earnings
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - HC Wainwright raised their FY2025 earnings per share estimates for Day One Biopharmaceuticals in a report released on Wednesday...
MarketBeat·5d ago
News Placeholder
What is Wedbush's Estimate for DAWN FY2025 Earnings?
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Equities research analysts at Wedbush increased their FY2025 earnings per share (EPS) estimates for shares of Day One Biopharmaceuticals...
MarketBeat·5d ago
News Placeholder
Equities Analysts Offer Predictions for DAWN FY2029 Earnings
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Stock analysts at HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for Day One Biopharmaceuticals in a research...
MarketBeat·6d ago
News Placeholder
Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Raised to $26.00
Piper Sandler upped their price target on shares of Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an "overweight" rating in a report on Wednesday...
MarketBeat·7d ago
News Placeholder
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Better-Than-Expected Earnings
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up on Strong Earnings...
MarketBeat·7d ago
News Placeholder
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q3 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of +32.14% and +5.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9d ago

Latest DAWN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.